XSHE
002950
Market cap823mUSD
Oct 09, Last price
9.01CNY
1D
3.56%
1Q
2.27%
IPO
-22.66%
Name
Allmed Medical Products Co Ltd
Chart & performance
P/E
22.93
P/S
1.55
EPS
0.39
Div yield, %
0.69%
Shrs. gr., 5y
-0.43%
Rev. gr., 5y
4.65%
Revenues
3.67b
+10.38%
Net income
249m
-32.49%
CFO
717m
+0.77%
Dividend
Jun 24, 20260.146 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Allmed Medical Products Co., Ltd. engages in the research, development, production and sales of disposable medical consumables. Its products include woven gauze swabs, non-woven swabs, elastic bandage, petrolatum gauze dress, oil emulsion dressing, eye pads, sponges, OR towels, kits, disposable drapes, dry, wet wipes, surgical gown, shoes and boot covers. The company was founded in 1992 and is headquartered in Zhijiang, China.
Key people
Jinhai Cui
Chairman of the Board, President · since 2022
Hong Cheng
Vice Chairman of the Board · since 2022
Chunjing Chen
Vice President · since 2025
Xingwei Cui
Vice President, Director · since 2025
Dongning Cui
Vice President, Director · since 2022
Hui Cui
Vice President, Director · since 2025
Tiezhu Huang
Chief Financial Officer, Vice President · since 2023
Huiqing Jia
Vice President, Director · since 2019
Yunsheng Li
Staff Elected Director · since 2025
Jiayue Wu
Director · since 2025
Independent Director · since 2022
Manli Cai
Independent Director · since 2022
Guangjun Tan
Independent Director · since 2022
Headquarters & legal address
枝江市马家店七星大道18号
宜昌市, HB 430000
CN
宜昌市, HB 430000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||||
Revenues | ||||||||||||
Cost of revenue | ||||||||||||
Unusual Expense (Income) | ||||||||||||
NOPBT | ||||||||||||
NOPBT Margin | ||||||||||||
Operating Taxes | ||||||||||||
Tax Rate | ||||||||||||
NOPAT | ||||||||||||
Net income | ||||||||||||
Dividends | ||||||||||||
Dividend yield | ||||||||||||
Proceeds from repurchase of equity | ||||||||||||
BB yield | ||||||||||||
| Debt | ||||||||||||
Debt current | ||||||||||||
Long-term debt | ||||||||||||
Deferred revenue | ||||||||||||
Other long-term liabilities | ||||||||||||
Net debt | ||||||||||||
| Cash flow | ||||||||||||
Cash from operating activities | ||||||||||||
CAPEX | ||||||||||||
Cash from investing activities | ||||||||||||
Cash from financing activities | ||||||||||||
FCF | ||||||||||||
| Balance | ||||||||||||
Cash | ||||||||||||
Long term investments | ||||||||||||
Excess cash | ||||||||||||
Stockholders' equity | ||||||||||||
Invested Capital | ||||||||||||
ROIC | ||||||||||||
ROCE | ||||||||||||
| EV | ||||||||||||
Common stock shares outstanding | ||||||||||||
Price | ||||||||||||
Market cap | ||||||||||||
EV | ||||||||||||
EBITDA | ||||||||||||
EV/EBITDA | ||||||||||||
Interest | ||||||||||||
Interest/NOPBT | ||||||||||||